Prognostic implication of IgG4 and IgG1-positive cell infiltration in the lung in patients with idiopathic interstitial pneumonia

Masamichi Komatsu1, Hiroshi Yamamoto1,2*, Takeshi Uehara2, Yukihiro Kobayashi1,2, Hironao Hozumi2, Tomoyuki Fujisawa1, Atsushi Miyamoto4, Tomoo Kishaba5, Fumihiro Kunishima6, Masaki Okamoto7, Hideya Kitamura8, Tae Iwasawa9, Shiochiro Matsushita10, Yasuhiro Terasaki11,12, Shinobu Kunugi11, Atsuhito Ushiki1, Masanori Yasuo1,13, Takafumi Suda3 and Masayuki Hanaoka1

Immunoglobulin (Ig) G4-positive cells are rarely observed in the lungs of patients with idiopathic interstitial pneumonias (IIPs). IgG1 may be more pathogenic than IgG4, with IgG4 having both pathogenic and protective roles in IgG4-related disease (IgG4-RD). However, the role of both IgG1 and IgG4 in IIPs remains unclear. We hypothesized that patients with IgG4-positive interstitial pneumonia manifest different clinical characteristics than patients with IgG4-RD. Herein, we identified the correlation of the degree of infiltration of IgG1- and IgG4-positive cells with IIP prognosis, using a Japanese nationwide cloud-based database. We included eighty-eight patients diagnosed with IIPs after multidisciplinary discussion, from April 2009 to March 2014. IgG4-positive cell infiltration was identified in 12/88 patients with IIPs and 8/41 patients with idiopathic pulmonary fibrosis (IPF). Additionally, 31/88 patients with IIPs and 19/41 patients with IPF were diagnosed as having IgG1-positive cell infiltration. IgG4-positive IIPs tended to have a better prognosis. Conversely, overall survival in cases with IgG1-positive IPF was significantly worse. IIPs were prevalent with IgG1- or IgG4-positive cell infiltration. IgG1-positive cell infiltration in IPF significantly correlated with a worse prognosis. Overall, evaluating the degree of IgG1-positive cell infiltration may be prognostically useful in cases of IPF.

Abbreviations

Blys  B lymphocyte stimulating factor
DIP  Desquamative interstitial pneumonia
DLco  Diffusing capacity of the lung for carbon monoxide
FVC  Forced vital capacity
HPF  High-power field

1First Department of Internal Medicine, Shinshu University School of Medicine, Matsumoto, Japan. 2Department of Laboratory Medicine, Shinshu University School of Medicine, Matsumoto, Japan. 3Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan. 4Department of Respiratory Medicine, Respiratory Center, Toranomon Hospital, Tokyo, Japan. 5Department of Respiratory Medicine, Okinawa Prefectural Chubu Hospital, Naha, Japan. 6Division of Pathology, Okinawa Prefectural Chubu Hospital, Naha, Japan. 7Division of Respiratory Medicine, Kurume University School of Medicine, Kurume, Japan. 8Division of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan. 9Department of Radiology, Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan. 10Department of Radiology, Yokohama City University Hospital, Yokohama, Japan. 11Department of Analytic Human Pathology, Nippon Medical School, Tokyo, Japan. 12Division of Pathology, Nippon Medical School Hospital, Tokyo, Japan. 13Department of Clinical Laboratory Sciences, Shinshu University School of Health Sciences, Matsumoto, Japan. *email: yama5252@shinshu-u.ac.jp
HRCT  High-resolution computed tomography
Ig  Immunoglobulin
IgG4-RD  Immunoglobulin G4-related disease
IgG4-RRD  Immunoglobulin G4-related respiratory disease
IIPs  Idiopathic interstitial pneumonias
iNSIP  Idiopathic non-specific interstitial pneumonia
IPAF  Interstitial pneumonia with autoimmune features
IPF  Idiopathic pulmonary fibrosis
MDD  Multidisciplinary discussion
OS  Overall survival
SLB  Surgical lung biopsy
UIP  Usual interstitial pneumonia

Immunoglobulin (Ig) G4-related disease (IgG4-RD) is a systemic disease characterised by an elevated serum IgG4 concentration and IgG4-positive plasma cell infiltration into multiple organs\(^1\),\(^2\). Up to 35% of patients with IgG4-RD present with intrathoracic lesions, including those involving the mediastinal lymph nodes, bronchial walls, and peribronchovascular bundles\(^3\),\(^4\). All lesions in the thorax have been comprehensively classified as IgG4-related respiratory disease (IgG4-RRD)\(^5\). However, the diagnosis of IgG-RRD is sometimes difficult and requires multidisciplinary discussion (MDD)\(^6\).

Additionally, various types of idiopathic interstitial pneumonia (IIP) with IgG4-positive plasma cell infiltration in the lungs\(^7\)–\(^14\) have been reported. Recently, we reported 16 cases with clinical characteristics of interstitial pneumonia, abundant IgG4-positive cells in the lungs and elevated serum IgG4 levels without extra-thoracic lesions\(^15\). In most cases, marked numbers of lymphoplasmacytic cells in the fibrous parenchyma were observed. In contrast, none of the 16 patients had either obliterative vasculitis or storiform fibrosis, which are characteristic of IgG4-RD. In addition, progressive fibrosis was observed despite glucocorticoid treatment. We speculate that these cases have IgG4-positive interstitial pneumonias, and should be given an alternative treatment compared to those with IgG4-RRD.

We thought that it was necessary to examine the frequency of IIPs with IgG4-positive cell infiltration in lung tissues and to investigate the clinical significance of IgG4-positive cell infiltration.

Furthermore, whether IgG4 antibodies are active in the pathogenesis of this disease also remains to be elucidated. IgG4 is considered to be a weak-inflammatory or more specifically anti-inflammatory Ig\(^16\). Recently, it has been suggested that IgG1 has pathogenic roles and IgG4 has both pathogenic and protective roles in IgG4-related pancreatitis (autoimmune pancreatitis)\(^17\). We speculated that IIPs with abundant IgG1-positive cells may have a poor prognosis regardless of the degree of IgG4-positive cells. However, the roles of IgG1 and IgG4 in patients with IIPs remain unclear. Therefore, it was necessary to examine the clinical characteristics of patients with IIPs with or without IgG1 as well as IgG4-positive cell infiltration.

In this study, we retrospectively analysed the presence of IgG-, IgG1-, and IgG4-positive cells by immunostaining surgical lung biopsy (SLB) specimens obtained from patients with IIPs. The patients’ diagnoses were confirmed by MDD. The current study is the largest survey of IgG4-positive cells in SLB specimens for IIPs and the first one evaluating IgG1-positive cell infiltration in SLB specimens for IIPs.

**Results**

**Patient characteristics and multidisciplinary discussion.** The MDD diagnoses of the 88 patients are shown in Table 1. The most prevalent MDD diagnosis was IPF (41 patients), followed by unclassifiable IIPs (28 patients). The patient characteristics for IIPs and IPF are described in Table 2. The median ages of diagnosis of IIPs and IPF were 65.0 and 66.0 years, respectively. In patients with IIP, serum IgG4 was analysed in 24 patients, and the median level of serum IgG4 was 40.5 mg/dL.
The median follow-up period in cases of IIPs was 3.93 years (range 0.05–12.59). During the follow-up period, acute exacerbation and lung cancer developed in 22 patients (25.0%) and three patients (3.4%), respectively. None of the patients developed extra-thoracic IgG4-RD. Thirteen patients died of chronic respiratory failure, six patients died from an acute exacerbation, and four patients died from an infection in the follow-up period. In IIPs, the median numbers of positive cells per high-power field (HPF) in the immunohistochemistry for IgG, IgG1, and IgG4 were 22, 14, and 2, respectively. The IgG1 + /IgG + ratio and IgG4 + /IgG + ratio were 67.3, and 6.5, respectively.

|                  | IIPs (N = 88) | IPF (N = 41) |
|------------------|--------------|--------------|
| Age, years       | 65.0 (20.0–78.0) | 66.0 (43.0–78.0) |
| Sex, male/female | 54 (60.8%)/34 (39.2%) | 24 (58.5%)/17 (41.5%) |
| Smoking, y/n     | 48 (54.5%)/40 (45.5%) | 21 (1.2%)/20 (48.8%) |
| MDD              |              |              |
| IPAF/non-IPAF    | 28/69        | 8/33         |
| **Immunohistochemistry** |         |              |
| IgG-positive cell/HPF | 22 (0–212)  | 28 (3–153)   |
| IgG1-positive cell/HPF | 14 (0–173)  | 30 (0–115)   |
| IgG4-positive cell/HPF | 2 (0–75)    | 1 (0–75)     |
| IgG1-positive cell/IgG-positive cell | 67.3 (0.0–350) | 73.9 (0.0–204.5) |
| IgG4-positive cell/IgG-positive cell | 6.5 (0.0–130.0) | 5.8 (0.0–64.1) |
| **Laboratory**   |              |              |
| LDH, U/L         | 231 (132–447) | 239 (185–2341) |
| KL-6, U/mL       | 1257 (151–16,120) | 1051 (338–4350) |
| SP-D, ng/mL      | 320 (45–1350) | 202 (55–401) |
| serum IgG4, mg/dL| 40.5 (8.0–372.0) | N = 24 |
|                  | 59.6 (13.0–372.0) | N = 9        |
| **Pulmonary function** | |              |
| FVC, L           | 2.46 (0.71–4.62) | 2.34 (0.71–3.76) |
| %FVC, %predicted | 78.0 (30.6–126.5) | 77.9 (30.6–126.5) |
| %DLco, %predicted | 65.0 (25.7–154.0) | 60.7 (27.7–114.8) |
| **6-min walk test** |             |              |
| Distance, meter  | 475 (200–660) | 450 (200–650) |
| min SpO2, %      | 93 (79–96) | 93 (79–96) |
| **Radiographic pattern** |      |              |
| Definite UIP/Possible UIP/Inconsistent with UIP | 3 (3.4%)/43 (48.9%)/40 (45.5%) | 3 (7.3%)/33 (80.5%)/ 5 (12.2%) |
| **Pathological pattern** |         |              |
| Definite UIP/Probable UIP/Possible UIP/ Not UIP | 12 (13.6%)/35 (39.8%)/18 (20.5%)/17 (19.3%) | 10 (24.4%)/20 (48.8%)/5 (12.2%)/0 (0.0%) |
| **Treatment**    |              |              |
| Corticosteroids  | 51 (58.0%) | 22 (53.7%) |
| Immunosuppressants | 23 (26.1%) | 8 (19.5%) |
| Antifibrotic drugs | 26 (29.5%) | 19 (46.3%) |
| **Follow-up, years** | 3.93 (0.05–12.59) | 3.30 (0.15–12.43) |
| **Clinical event** |             |              |
| Acute exacerbation | 22 (25.0%) | 11 (26.8%) |
| Lung cancer      | 3 (3.4%) | 2 (4.9%) |
| Dead cases       | 27 (30.7%) | 16 (39.0%) |
| **Cause of death** |         |              |
| Chronic respiratory failure | 13 | 7 |
| Acute exacerbation | 6 | 4 |
| Infection | 4 | 2 |
| Others | 4 | 3 |

Table 2. Characteristics of patients with IIPs and IPF. Data are presented as the median (range) or N (%). DLco diffusing capacity of the lung for carbon monoxide, FVC forced vital capacity, HPF high-power field, Ig immunoglobulin, IIP idiopathic interstitial pneumonia, IPAF interstitial pneumonia with autoimmunue features, IPF idiopathic pulmonary fibrosis, KL-6 Krebs von Lungen-6, LDH lactate dehydrogenase, MDD multidisciplinary discussion, SP surfactant protein, UIP usual interstitial pneumonia, y/n yes/no.

The median follow-up period in cases of IIPs was 3.93 years (range 0.05–12.59). During the follow-up period, acute exacerbation and lung cancer developed in 22 patients (25.0%) and three patients (3.4%), respectively. None of the patients developed extra-thoracic IgG4-RD. Thirteen patients died of chronic respiratory failure, six patients died from an acute exacerbation, and four patients died from an infection in the follow-up period. In IIPs, the median numbers of positive cells per high-power field (HPF) in the immunohistochemistry for IgG, IgG1, and IgG4 were 22, 14, and 2, respectively. The IgG1 + /IgG + ratio and IgG4 + /IgG + ratio were 67.3, and 6.5, respectively.
Table 3. Characteristics of patients with IIPs and IPF with or without IgG4-positive cell infiltration. Data are presented as the median (range), or N (%). Bold font: *p*-value < 0.05. DLco: diffusing capacity of the lung for carbon monoxide, FVC: forced vital capacity, HFP: high-power field, IgM: immunoglobulin M, IgG: immunoglobulin G, IgG1: immunoglobulin G1, IgG4: immunoglobulin G4, IPF: idiopathic pulmonary fibrosis, IIP: idiopathic interstitial pneumonia, IPAF: interstitial pneumonia with autoimmune features, MDD: multidisciplinary discussion, SP-d: surfactant protein D, y/n: yes/no.

In the IPF group, the median numbers of positive cells per HPF in the immunohistochemistry analysis for IgG, IgG1, and IgG4 were 28, 30, and 1, respectively. The IgG1 + /IgG + ratio and IgG4 + /IgG + ratio were 73.9 and 5.8, respectively.

The degrees of IgG1-positive cells and IgG4-positive cells in cases of IIPs are summarised in Table 1. Furthermore, there was a positive correlation between serum IgG4 and IgG4-positive cells/HPF (rs = 0.693, *p* < 0.02) (Supplementary Figs. S1, S2 online).

Definition of IgG1- or IgG4-positive IIPs. In this study, if the IgG4-positive cells were scored 2 or more (>10/HPF), IgG4-positive IIP was diagnosed with reference to the proposed IgG4-RRD diagnostic criteria. Among patients with IIP, 12 of 88 patients (13.6%) were diagnosed as having IgG4-positive IIPs; among patients with IPF, 8 of 41 patients (19.5%) were diagnosed as having IgG4-positive IPF, according to this definition. Similarly, one of nine patients with idiopathic nonspecific interstitial pneumonia (NSIP) patients (11.1%) and one of six desquamative interstitial pneumonia (DIP) patients (16.7%), was diagnosed as having IgG4-positive IIPs (Table 1).

In this study, the cells with a score greater than 3 (>30/HPF) with reference to the median number of IgG1-positive cells in IPF were defined as IgG1-positive cells. Among the 88 patients with IIP, 31 (35.2%) were diagnosed as having IgG1-positive cells and IgG4-positive cells (rs = 0.477, *p* = 0.02) (Supplementary Figs. S1, S2 online).

Comparison of IIPs and IPF with or without IgG4-positive cells. We compared the patients with IIPs and IPF with or without IgG4-positive cell infiltration (IgG4-positive or negative IIPs, as well as IgG4-positive or negative IPF).

The characteristics of the groups are summarised in Table 3. In both the IIPs and IPF groups, the serum levels of IgG4 were significantly higher in IgG4-positive patients than in IgG4-negative patients. In immunohistochemistry, IgG- and IgG1-positive cells/HPF, and IgG4 + /IgG + ratio were significantly high in both IgG4-positive groups. In the physiological tests, the predicted percentage of the diffusing capacity of the lung for carbon monoxide, FVC forced vital capacity, HFP: high-power field, IgM: immunoglobulin M, IgG: immunoglobulin G, IgG1: immunoglobulin G1, IgG4: immunoglobulin G4, IPF: idiopathic pulmonary fibrosis, IIP: idiopathic interstitial pneumonia, IPAF: interstitial pneumonia with autoimmune features, MDD: multidisciplinary discussion, SP-d: surfactant protein D, y/n: yes/no.
carbon monoxide (DLco) was significantly lower in IgG4-positive IPF than in IgG4-negative IPF. The frequency of patients who fulfilled the criteria for diagnosis of interstitial pneumonia with autoimmune features (IPAF) did not differ between the two groups. Detailed clinical features and serum autoantibody positivity are listed in Supplementary Table S1 online.

The Kaplan–Meier curves of overall survival (OS) for patients with or without IgG4-positive cells are shown in Fig. 1. Although there were no statistical differences between the two groups, the prognosis of IgG4-positive IIPs tended to be better than that of IgG4-negative IIPs (Fig. 1a). In contrast, there were no differences in survival for patients with IPF between the groups of patients with or without IgG4-positive cells (Fig. 1b).

Comparison of IIPs and IPF with or without IgG1-positive cells. We compared the patients with IIPs and IPF with or without IgG1-positive cell infiltration (IgG1-positive, or negative IIPs, as well as IgG1-positive or negative IPF). The characteristics of the groups are summarised in Table 4. In immunohistochemistry, IgG- and IgG1-positive cells/HPF, and IgG1+/IgG + ratio were significantly high in both IgG1-positive groups. There were no differences between the two groups in the baseline values obtained from the pulmonary function tests. In the 6-min walk test, there was no difference in the distance, but the lowest arterial oxygen saturation measured with pulse oximetry was significantly lower in the IgG1-positive IPF group than in the IgG1-negative IPF group.

The Kaplan–Meier curves of OS for the IgG1-positive or IgG1-negative group are shown in Fig. 2. There were statistically significant differences in survival between IgG1-positive IPF and IgG1-negative IPF (Fig. 2b). The univariate Cox proportional hazards regression analysis showed that IgG1-positive cell > 30/HPF (hazard ratio [HR] 3.411, 95% confidence intervals [CI] 1.127–10.322; \( p = 0.030 \)) and the incidence of acute exacerbation (HR 3.241, 95% CI 1.123–9.356; \( p = 0.030 \)) were associated with a high risk of death. The multivariate analysis showed that IgG1-positive cell > 30/HPF (HR 4.069, 95% CI 1.252–13.230; \( p = 0.020 \)) and the incidence of acute exacerbation (HR 4.073, 95% CI 1.370–12.114; \( p = 0.012 \)) were independently associated with a high risk of death (Table 5).

Discussion

To the best of our knowledge, this is the most comprehensive report on the prevalence of IgG4-positive cell infiltration in SLB specimens of patients with IIPs and the first study of IgG1-positive cell infiltration in these specimens. We found that 19.5% of IPF, 11.1% of iNSIP, and 16.7% of patients with DIP had IgG4-positive IIPs. We also found that patients with IgG4-positive IIPs had a tendency toward a better survival rate than the IgG4-negative IIPs. In addition, patients with IgG1-positive IPF had a significantly worse survival rate than patients with IgG1-negative IPF. This trend was more pronounced when the threshold was changed to 40 cells/HPF (Supplementary Fig. S3 online). Thus, evaluation of IgG1- and IgG4-positive cell infiltration in IIPs might be a useful prognostic tool.

Shrestha et al. reported that IgG4-positive cells > 10/HPF were found in 25% of usual interstitial pneumonia (UIP) and 10% of NSIP\(^5\). This frequency of IgG4-positive plasma cells in IIPs is comparable to the findings in
Table 4. Characteristics of patients with IIPs and IPF with or without IgG1-positive cell infiltration. Data are presented as the median (range) or N (%). Bold font: p-value < 0.05. DLco, diffusing capacity of the lung for carbon monoxide; FVC, forced vital capacity; GAP, gender, age, physiological variable; HFP, high-power field; Ig, immunoglobulin; IIP, idiopathic interstitial pneumonia; IPAF, interstitial pneumonia with autoimmune features; IPF, idiopathic pulmonary fibrosis; KL-6, Krebs von Lungen-6; LDH, lactate dehydrogenase; MDD, multidisciplinary discussion; N.E., not applicable; SP, surfactant protein; y/n, yes/no.

|                        | IgG1-positive IIPs (N = 31) | IgG1-negative IIPs (N = 57) | p-value | IgG1-positive IPF (N = 19) | IgG1-negative IPF (N = 22) | p-value |
|------------------------|-----------------------------|-----------------------------|---------|---------------------------|---------------------------|---------|
| Age, years             | 64.0 (20.0–75.0)            | 66.0 (25.0–78.0)            | 0.185   | 66.0 (54.0–74.0)          | 67.5 (43.0–78.0)          | 0.838   |
| Sex, male/female       | 18 (58.1%)/13 (41.9%)       | 36 (63.2%)/21 (36.8%)       | 0.639   | 10 (52.6%)/9 (47.4%)      | 14 (63.6%)/8 (36.4%)      | 0.476   |
| Smoking, y/n           | 6 (42.9%)/16 (51.6%)        | 33 (57.9%)/24 (42.1%)       | 0.392   | 9 (47.4%)/10 (52.6%)      | 12 (54.5%)/10 (45.5%)     | 0.647   |
| MDD                    |                             |                             |         |                           |                           |         |
| IPAF/non-IPAF          | 10/21                       | 15/42                       | 0.555   | 5/14                      | 3/19                      | 0.4361  |
| Immunohistochemistry   |                             |                             |         |                           |                           |         |
| IgG-positive cell/HPF  | 74 (10–212)                 | 14 (0–117)                  | <0.001  | 67 (20–153)               | 17 (3–117)                | <0.001  |
| IgG1-positive cell/HPF | 49 (32–175)                 | 6 (0–30)                    | <0.001  | 71 (32–115)               | 9 (0–30)                  | <0.001  |
| IgG4-positive cell/HPF | 5 (0–65)                    | 1 (0–30)                    | 0.004   | 6 (0–65)                  | 1 (0–75)                  | 0.102   |
| IgG1-positive cell/IgG-positive cell | 94.7 (36.2–350.0) | 42.3 (0.0–187.5) | <0.001 | 94.7 (36.2–204.5) | 51.0 (0.0–187.5) | <0.001 |
| IgG4-positive cell/IgG-positive cell | 10.0 (0.0–130.0) | 5.3 (0.0–85.7) | 0.709 | 11.7 (0.0–42.5) | 0.7 (0.0–64.1) | 0.131 |
| Laboratory             |                             |                             |         |                           |                           |         |
| LDH, U/L               | 247 (162–361)               | 223 (132–447)               | 0.127   | 247 (193–355)             | 224 (182–447)             | 0.380   |
| KL-6, U/mL             | 1508 (151–16120)            | 1175 (221–5646)             | 0.101   | 1508 (151–16120)          | 976 (348–3030)            | 0.092   |
| SP-D, ng/mL            | 293 (74–1350)               | 195 (45–786)                | 0.023   | 365 (74–1350)             | 155 (69–333)              | 0.018   |
| serum IgG4, mg/dL      | 49.0 (8.0–372.0) N = 4      | 40.5 (9.3–177.0) N = 20     | 0.122   | 85.0 (13.0–372.0) N = 3    | 50.1 (16.3–124.0) N = 6   | 0.246   |
| Pulmonary function     |                             |                             |         |                           |                           |         |
| FVC, L                 | 2.45 (0.7–3.64)             | 2.46 (1.06–4.62)            | 0.317   | 2.28 (0.71–3.31)          | 2.39 (1.06–3.76)          | 0.475   |
| %FVC, %predicted       | 77.4 (30.6–110.4)           | 79.0 (31.5–126.5)           | 0.223   | 74.6 (30.6–110.4)         | 81.8 (31.5–126.5)         | 0.506   |
| %DLco, %predicted      | 59.6 (25.7–124.5)           | 67.0 (27.7–154.0)           | 0.598   | 57.8 (36.2–114.8)         | 66.7 (27.7–108.0)         | 0.633   |
| 6-min walk test        |                             |                             |         |                           |                           |         |
| Distance, m            | 469 (230–650)               | 500 (200–660)               | 0.566   | 455 (230–650)             | 450 (200–640)             | 0.731   |
| min SpO2, %            | 92 (79–95)                  | 93 (83–96)                  | 0.223   | 90 (79–95)                | 93 (88–96)                | 0.013   |
| GAP index              |                             |                             |         |                           |                           | 0.703   |
| Stage I                | N/E                         | N/E                         |         | 10 (71.4%)                | 14 (77.8%)                |         |
| Stage II               | N/E                         | N/E                         |         | 4 (28.6%)                 | 4 (22.2%)                 |         |

our study, Ikeda et al. reported that IIPs with abundant IgG4-positive cells had a good response to corticosteroid monotherapy. In the present study, the prognosis of IgG4-positive IIPs tended to be better than that of IgG4-negative IIPs. Further investigation remains warranted to clarify the prognosis of IIPs with or without IgG4-positive cell infiltration.

Recently, we defined IgG4-positive interstitial pneumonia as a condition with elevated serum IgG4 concentrations (≥ 135 mg/dL) and infiltration of abundant IgG4-positive plasma cells (IgG4+ /IgG+ ratio > 40%; IgG4-positive cells > 10 per HPF)15. Herein, 6 of 88 patients with IIP and 3 of 41 patients with IPF fulfilled both conditions of > 40% IgG4+/IgG+ ratio and > 10 IgG4-positive cells per HPF. Notably, none of the patients developed IgG4-RD. It was plausable that IgG4-positive cells were expressed in IIPs independent of IgG4-RD, although only a few patients were evaluated for serum IgG4 concentration.

On the contrary, IgG1-positive IPF showed a significantly worse survival rate than did IgG1-negative IPF. In immunohistochemistry, IgG1-positive cells are IgG1-positive plasma cells or lymphoid cells containing IgG1. It might be considered that IgG1-positive IPF means IPF involving B cells. Although a precise understanding of the relationship between B cells and IPF remains elusive, there are some existing reports on B cells and IPF20. Xue et al. reported that patients with IPF who had enriched B lymphocyte stimulating factor (BLyS) had a worse survival rate than those with lower levels of BLyS19. Although further research is warranted, IgG1-positive cells in SLB specimens may be a prognostic indicator of patients with IPF. Therefore, the use of antibirotic agents in the early stage of IPF or new therapeutic strategies may be required in cases of IPF that also have abundant IgG1-positive cells in the lung. However, further studies are needed to clarify this problem.

In this study, the evaluation of IgG1-positive cells was performed at the sites with abundant IgG4-positive cells. There was no consistent trend in the degree of infiltration by IgG1 and IgG4-positive cells. The present study did not prove that IgG1 is responsive to IgG4. In the future, it will be necessary to evaluate whether IgG4 is found around fibrotic foci or fibrosis to assess whether IgG4 plays a protective role. On the other hand, it has been suggested that abundant IgG1-positive cells, regardless of IgG4-positive cells, is considered a poor prognostic factor of IPF.

The pathogenicity of IgG4-RD remains to be elucidated. It also remains to be determined whether IgG4 antibodies are active in the pathogenesis of IgG4-RD. IgG4 cannot activate the classical complement pathway.
and has a low affinity for Fc receptors. IgG4 is considered weak-inflammatory; rather it has the potential to cause a reduction in the immune activation of IgG16. Shiokawa et al. revealed that subcutaneous injections of IgG from patients with autoimmune pancreatitis (pancreatic lesion of IgG4-RD) led to organ injuries in a mouse model. Organ injury was also induced by injecting IgG1 and IgG4 from these patients into mice; IgG1 injection caused more destructive changes compared to IgG4. Moreover, organ destruction was more effectively inhibited by simultaneous injections of patient-derived IgG1 and IgG4 than by injection of patient-derived IgG1 alone. The observations suggest that IgG4 antibodies act against pathogenic IgG1 antibodies. Fujimoto et al. reported that in patients with stage I squamous cell lung cancers, IgG4-positive cell infiltration around the tumour in the resected lung specimens corresponded with a favourable prognosis. These phenomena are compatible with our findings that IIPs with IgG4-positive cell infiltration showed a tendency toward a better prognosis and that IPF with IgG1-positive cell infiltration had a significantly worse prognosis. IgG1 and IgG4 immunostaining may be beneficial for IIPs because it may predict prognosis and inform therapeutic management decisions.

Figure 2. Survival curves of patients with either IIPs or IPF with or without IgG1-positive cell infiltration. (a) The Kaplan–Meier curve of the overall survival of patients with idiopathic interstitial pneumonias with or without IgG1-positive cell infiltration in the lungs (IgG1-positive or negative IIPs). (Solid line: IgG1-positive IIPs, Broken line: IgG1-negative IIPs). (b) The Kaplan–Meier curve of the overall survival of patients with idiopathic pulmonary fibrosis with or without IgG1-positive cell infiltration in the lungs (IgG1-positive or negative IPF). CI confidence interval, Ig immunoglobulin, IIP idiopathic interstitial pneumonia, IPF idiopathic pulmonary fibrosis, N.E. not evaluable, OS overall survival.

Table 5. Univariate and multivariate Cox proportional hazard regression analysis of the death risk in patients with IPF. Bold font: p-value < 0.05. CI confidence interval, DLco diffusing capacity of the lung for carbon monoxide, FVC forced vital capacity, GAP gender, age, physiological variable, HPF high-power field, HR hazard ratio, Ig immunoglobulin, IIP idiopathic interstitial pneumonia, IPF idiopathic pulmonary fibrosis, KL-6 Krebs von Lungen-6, SP surfactant protein.
This study has several limitations. The nationwide, cloud-based database does not include serum IgG or IgG4 levels; therefore, we obtained these from the clinical records of each institution. Almost all institutions in this study did not routinely test for serum IgG and IgG4; thus, we could only obtain a small sample number. Additionally, the study was not large enough to reach definite conclusions on the prognosis of IIPs with or without IgG4-positive cell infiltration. Despite these limitations, to the best of our knowledge, this is the first report describing IgG-, IgG1-, and IgG4-positive cell infiltration in SLB specimens for IIPs diagnosed by a centralised MDD.

In summary, we revealed the prevalence of IgG4-positive cell infiltration in SLB specimens from patients with IIPs in Japan. The prognosis of IIPs with IgG4-positive cell infiltration tended to be better than those without IgG4-positive cell infiltration. Furthermore, IIPs with IgG1-positive cell infiltration had a significantly worse prognosis than those without IgG1-positive cell infiltration. Overall, evaluations of the degree of IgG1-positive cell infiltration may be prognostically useful in cases of IPF.

Methods

Study subjects. This study is a secondary survey of data from a retrospective study25. We used a nationwide cloud-based integrated database of IIPs after centralised MDD. Details of the database have been described previously25. Information on 524 patients who underwent SLB from April 2009 to March 2014 was collected from 39 institutions throughout Japan. The cloud-based database was constructed including clinico-radiological-pathological data. Web-based MDD was performed using the database.

In this study, we enrolled 88 patients from five institutions for whom re-pathological analysis was possible. We reviewed the glass slides of SLB from the 88 cases. The institutional review board approved the study protocol (the Ethics Committee of the Shinshu University School of Medicine, Approval Number: 4205) and each institution approved the study protocol (the Ethics Committee of the Hamamatsu University School of Medicine, Approval Number: 2019-0009; Toranomon Hospital, Approval Number: 1773; Prefectural Chubu Hospital, Approval Number: 2018-120; Kurume University School of Medicine, Approval Number: 18221). This study was performed in accordance with the Declaration of Helsinki and its subsequent amendments. The need for obtaining patient written informed consent was waived, owing to the retrospective nature of this study.

Clinical, laboratory, and physiology findings. Clinical information was obtained from the database for each patient. Although serum levels of IgG, IgG1, and IgG4 were not included in the database, the serum level of IgG4 for 24 of the 88 patients was obtained from the clinical records from each institution. The incidence of acute exacerbation and lung cancer was also obtained from the database. Inadequate items in the database were excluded.

In our cohort, non-IIPs such as sarcoidosis, hypersensitivity pneumonia, or collagen vascular disease-associated interstitial pneumonia were excluded by MDD. Clinical, serologic, and morphological domains were evaluated based on the criterion of IPAF26.

Clinical characteristics of IgG4-positive or negative IIPs, as well as IgG1-positive or negative IIPs, were analysed. In addition, we analysed clinical characteristics of IgG4-positive or negative IPF, as well as IgG1-positive or negative IPF.

Imaging. All high-resolution computed tomography (HRCT) chest images obtained within three months of the SLB were analysed. The radiologists determined the HRCT pattern of IIPs according to the 2011 guidelines28 of IPF: definite UIP, possible UIP, or inconsistent with UIP pattern.

Histopathological findings. The pathologists classified the samples from the SLB according to the 2011 guidelines of IPF classification26: definite UIP, probable UIP, possible UIP, and not UIP pattern. The pathologists also determined the histological patterns of IIPs according to the statement of classification for IIPs29.

In this study, SLB specimens were stained with haematoxylin–eosin and immuno-stained for IgG, IgG1, and IgG4. IgG immunohistochemical staining was performed using monoclonal IgG antibody (Leica, Lincolnshire, IL, USA). IgG1 and IgG4 immunohistochemical staining were performed using polyclonal antibodies against IgG1 and IgG4 (Binding Site, Birmingham, UK). The areas with the highest density of IgG4-positive cells, identified using immunostaining, were observed under a low-power field. A trained pathologist (T.U.) counted the IgG4-positive cells per HFP. IgG-positive cells/HFP and IgG1-positive cells/HFP were also counted in the same areas where IgG4-positive cells were evaluated. Representative pathological findings are shown in Supplementary Fig. S4 online. The ratio of IgG1-positive cells to IgG-positive cells (IgG1+/IgG+) as well as IgG4+/IgG1+ was also evaluated. IgG4-positive cells were scored according to the following criteria: IgG4 score 0, <5/HFP; score 1, 5 to 10/HFP; score 2, 11 to 30/HFP; and score 3, >30/HFP, as described in autoimmune pancreatitis25. IgG1-positive cells were scored in the same way.

Statistical analysis. Continuous data are presented as median and range, and categorical data are presented as a numerical value in each group. While the Mann–Whitney U test or unpaired t-test was used to compare continuous variables between the two groups, the chi² test or Fisher’s exact test was used to compare categorical variables. The OS, median, and 95% CIs were determined using the Kaplan–Meier method. The differences between groups were compared using the log-rank test. The univariate Cox proportional hazards regression analysis followed by a multivariate analysis was used to identify the determinants of a high risk of death. Correlations between the groups were examined using the Spearman’s rank correlation test. Variables with a p-value <0.05 in the univariate analyses were considered for inclusion in the multivariate model. Statis-
Ethics declarations. This study was approved by the Ethics Committee of the Shinshu University School of Medicine (Approval Number 4205), Hamamatsu University School of Medicine (Approval Number: 2019-0009), Toranomon Hospital (Approval Number: 1773), Prefectural Chubu Hospital (Approval Number: 2018-120) and Kurume University School of Medicine (Approval Number: 18221). This study was performed in accordance with the Declaration of Helsinki and its subsequent amendments. The need for obtaining patient written informed consent was waived, owing to the retrospective nature of this study (the Ethics Committee of the Shinshu University School of Medicine, Approval Number 4205, Nov 6, 2018).

Data availability. The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.

Received: 27 October 2021; Accepted: 23 May 2022

Published online: 03 June 2022

References
1. Umehara, H. et al. Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011. Mod. Rheumatol. 21, 21–30. https://doi.org/10.1007/s10166-011-0571-x (2012).
2. Wallace, Z. S. et al. The 2019 American College of Rheumatology/European League against rheumatism classification criteria for IgG4-related disease. Arthritis Rheumatol. 72, 7–19. https://doi.org/10.1002/art.41120 (2020).
3. Fei, Y. et al. Intrathoracic involvements of immunoglobulin G4-related sclerosing disease. Medicine 94, e2150. https://doi.org/10.1097/md.000000000002150 (2015).
4. Yamada, K. et al. IgG4-related disease: Is this finding specific to IgG4-related lung disease? Intern. Med. 56, 8110 (2017).
5. Matsui, S. et al. Proposed diagnostic criteria for IgG4-related respiratory disease. Respir. Investig. 54, 130–132. https://doi.org/10.1016/j.resinv.2015.09.002 (2016).
6. Matsui, S. et al. Clinical characteristics of immunoglobulin G4-positive plasma cells infiltration, which was thought as pulmonary involvement of IgG4-related autoimmune disease. Intern. Med. 47, 291–294. https://doi.org/10.2169/internalmedicine.47.0411 (2008).
7. Shikokawa, M. et al. Pathogenicity of IgG in patients with IgG4-related disease. Gut 65, 1322–1332. https://doi.org/10.1136/gutjnl-2015-310336 (2016).
8. Shrestha, R. et al. Distinctive pulmonary histopathology with increased IgG4-positive plasma cells in patients with autoimmune pancreatitis: Report of 6 and 12 cases with similar histopathology. Am. J. Surg. Pathol. 33, 1450–1462. https://doi.org/10.1097/PAS.0b013e3181ac43b6 (2009).
9. Ikeda, S. et al. Abundant immunoglobulin (Ig)G4-positive plasma cells in interstitial pneumonia without extrathoracic lesions of IgG4-related disease: Is this finding specific to IgG4-related lung disease? Histopathology 70, 242–252. https://doi.org/10.1111/his.13053 (2017).
10. Francois, A. et al. B cell activating factor is central to bleomycin- and IL-17-mediated experimental pulmonary fibrosis. J. Autoimmun. 56, 1–11. https://doi.org/10.1016/j.jaut.2014.08.003 (2015).
11. Xue, J. et al. Plasma B lymphocyte stimulator and B cell differentiation in idiopathic pulmonary fibrosis patients. J. Immunol. 191, 2089–2095. https://doi.org/10.4049/jimmunol.1203476 (2013).
12. van der Neud Kolfschoten, M. et al. Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science 317, 1554–1557. https://doi.org/10.1126/science.1146603 (2007).
13. Vidarsson, G., Dekkers, G. & Rispens, T. IgG subclasses and allotypes: From structure to effector functions. Front. Immunol. 5, 520. https://doi.org/10.3389/fimmu.2014.00520 (2014).
14. Fujimoto, M. et al. Stromal plasma cells expressing immunoglobulin G4 subclass in non-small cell lung cancer. Hum. Pathol. 44, 1569–1576. https://doi.org/10.1016/j.humpath.2013.01.003 (2013).
15. Fujisawa, T. et al. Nationwide cloud-based integrated database of idiopathic interstitial pneumonias for multidisciplinary discussion. Eur. Respir. J. 53, 1802243. https://doi.org/10.1183/13993003.02243-2018 (2019).
16. Fischer, A. et al. An official European Respiratory Society/American Thoracic Society research statement: Interstitial pneumonia with autoimmune features. Eur. Respir. J. 46, 976–987. https://doi.org/10.1183/13993003.0150-2015 (2015).
17. Ley, B. et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann. Intern. Med. 156, 684–691. https://doi.org/10.7326/m11-0481 (2012).
18. Raghu, G. et al. An official ATS/ERS/JRS/ALAT statement: Idiopathic pulmonary fibrosis: Evidence-based guidelines for diagnosis and management. Am. J. Respir. Crit. Care Med. 183, 788–824. https://doi.org/10.1164/rccm.2009-040GL (2011).
29. Travis, W. D. et al. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. *Am. J. Respir. Crit. Care Med.* **188**, 733–748. https://doi.org/10.1164/rccm.201308-1483ST (2013).

30. Zhang, L., Notohara, K., Levy, M. J., Chari, S. T. & Smyrk, T. C. IgG4-positive plasma cell infiltration in the diagnosis of autoimmune pancreatitis. *Mod. Pathol.* **20**, 23–28. https://doi.org/10.1038/modpathol.3800689 (2007).

**Acknowledgements**

This study was supported by the Ministry of Health, Labor, and Welfare Research Program on Rare and Intractable Disease (No. JPMH20FC1040) and the Japan Society for the Promotion of Science (No. 21K08175). We would like to thank Editage (www.editage.jp) for English language editing.

**Author contributions**

M.K.: concept and design of the work, acquisition, analysis and interpretation of data, statistical analysis, and manuscript writing. H.Y.: concept and design of the work, acquisition, analysis of data, administrative support, and manuscript writing. Y.K., T.U.: analysis and interpretation of data. H.H., T.F.: concept, acquisition, and analysis of data. A.M., T.K., F.K., M.O.: acquisition of data. H.K., T.I., S.M., Y.T., S.K.: analysis of data. A.U., M.Y.: analysis and interpretation of data. T.S.: concept, acquisition and analysis of data. M.H.: concept and design of the work, administrative support, and manuscript writing. All authors read and approved the final manuscript.

**Competing interests**

The authors declare no competing interests.

**Additional information**

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1038/s41598-022-13333-8.

Correspondence and requests for materials should be addressed to H.Y.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

[Open Access] This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022